I-Mab Files 6-K Report for Q2 2025

TL;DR

I-Mab dropped its Q2 2025 6-K, check the latest financials and incentive plan updates.

AI Summary

I-Mab filed a 6-K report on October 6, 2025, for the period ending June 30, 2025. The filing includes financial information and details related to share-based compensation plans, such as the 2025 Omnibus Share Incentive Plan. It also references subsequent events and operational segments for the periods ending June 30, 2024, and June 30, 2025.

Why It Matters

This filing provides investors with updated financial and operational information for I-Mab, crucial for assessing the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine 6-K filing providing financial updates and is not indicative of immediate company-specific risk.

Key Players & Entities

• I-Mab (company) — Filer
• 2025 Omnibus Share Incentive Plan (plan) — Share-based compensation
• June 30, 2025 (date) — Reporting period end
• June 30, 2024 (date) — Prior period comparison

FAQ

Key Financial Figures

• $80 m — deration of the RMB equivalent of up to $80 million, contingent on the achievement of
• $0.0001 — , 76,666,659 ordinary shares, par value $0.0001 per share, of the Company at an offerin
• $1.95 — of the Company at an offering price of $1.95 per ADS. Net proceeds from the Offering
• $61.2 million — enses payable by us, were approximately $61.2 million. We intend to use the net proceeds fr
• $1.8 million — alth shareholders an upfront payment of $1.8 million and non-contingent payments of $1.2 mil
• $1.2 million — million and non-contingent payments of $1.2 million through 2027. In addition, Bridge Healt
• $3.875 m — eive future milestone payments of up to $3.875 million, subject to the achievement of ce
• $4.1 million — ed research and development expenses of $4.1 million and $11.3 million for the six months en
• $11.3 million — evelopment expenses of $4.1 million and $11.3 million for the six months ended June 30, 2025
• $8.3 million — our administrative expenses amounted to $8.3 million and $14.4 million, respectively. Inte
• $14.4 m — e expenses amounted to $8.3 million and $14.4 million, respectively. Interest Income
• $7.2 m — h and development expenses decreased by $7.2 million, or 63.9%, from $11.3 million for
• $6.1 m — ur administrative expenses decreased by $6.1 million, or 42.2%, from $14.4 million for
• $14.4 million — creased by $6.1 million, or 42.2%, from $14.4 million for the six months ended June 30, 2024
• $3.7 million — Income We recorded interest income of $3.7 million and $2.8 million for the six months end

Filing Documents

• imab-20250630.htm (6-K) — 1784KB
• 0001193125-25-230890.txt ( ) — 10019KB
• imab-20250630.xsd (EX-101.SCH) — 2259KB
• imab-20250630_htm.xml (XML) — 1476KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph Skelton Title : Chief Financial Officer Date: October 6, 2025 3 TABLE OF CONTENTS Page

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 5

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 7 Overview 7 Recent Business Developments 7 Key Factors Affecting Our Results of Operations 8 Key Components of Results of Operations 9 Results of Operations 11 Critical Accounting Policies and Significant Judgments and Estimates 12 Liquidity and Capital Resources 13 Holding Company Structure 14 INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 F- 2 Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2025 and 2024 F- 3 Condensed Consolidated Statements of Changes in Shareholders' Equity for the Six Months Ended June 30, 2025 and 2024 F- 4 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 F- 5 Notes to the Condensed Consolidated Financial Statements F- 6 4

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Form 6-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("the Exchange Act"). All statements other than statements of present and historical facts and conditions are forward-looking statements. Forward-looking statements can often be identified by words or phrases, such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or the negative of such words or other similar expressions. Such forward-looking statements reflect our current expectations and views of future events, but are not assurances of future performance. Instead, they reflect our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our financial needs, our operational results and other future conditions based on information currently available to us. Such forward-looking statements included in this Form 6-K include, but are not limited to, statements relating to: the timing of initiation and completion, and the progress of our drug discovery and research programs; the timing and likelihood of regulatory filings and approvals; our ability to advance our drug candidates into drugs, and the successful completion of clinical trials; the approval, pricing and reimbursement of our drug candidates; the commercialization of our drug candidates; the market opportunities and competitive landscape of our drug candidates; the payment, receipt and timing of any milestone payments in relation to the licensing agreements; estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing; our ability to attract and retain senior management and key employees; our future business development, financial condition and results of o

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Our investors should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes for the six months ended June 30, 2025, as well as our audited consolidated financial statements and related notes for the year ended December 31, 2024 included in our Annual Report on Form 20-F, filed with the Securities and Exchange Commission (the "SEC"), on April 3, 2025. In this MD&A, unless otherwise indicated or the context otherwise requires, "we," "us," "our," the "Company," the "Group" and "I-Mab" refer to I-Mab, a Cayman Islands exempted company, and its consolidated subsidiaries, unless the context otherwise required. This MD&A includes trademarks, trade names and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, trade names and service marks referred to in this MD&A appear without the , and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, trade names and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties' trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. For the periods presented in our condensed consolidated financial statements included elsewhere in this MD&A, our reporting currency is U.S dollars. All references in this MD&A to "$" are to U.S. dollars, and all referen

View Full Filing

View this 6-K filing on SEC EDGAR